Robert Rifkin

Jan 21, 2025 | onclive.com | Robert Rifkin

“The thing to take away is [belantamab mafodotin-blmf (Blenrep)] will give your patients an opportunity to have exposure to a BCMA-targeted drug, either alone or in combination. It’ll be very useful for people who don’t have ready access to bispecific [antibodies] or CAR T-cell therapy.”Robert M.

Jan 6, 2025 | ajmc.com | Robert Rifkin

OpinionVideoJanuary 6, 2025Author(s):Robert M. Rifkin, MD, FACP, discusses how the MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition sheds light on elranatamab’s role in relapsed/refractory multiple myeloma while panelists discuss how emerging data on bispecific antibodies and combination strategies could shape treatment timing and improve outcomes, especially in heavily pretreated patients.

Dec 9, 2024 | onclive.com | Robert Rifkin

CommentaryVideoDecember 9, 2024Author(s):Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma. Robert M. Rifkin, MD, FACP, medical oncologist, hematologist, Rocky Mountain Cancer Centers, discusses overall survival analysis and efficacy outcomes from the phase 3 Dreamm-7 trial (NCT04246047) in patients with relapsed/refractory multiple myeloma.

Jun 24, 2024 | onclive.com | Robert Rifkin

Robert M.

Sep 19, 2023 | nature.com | Robert Rifkin

AbstractLong-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to toxicity, comorbidities, and the burden of repeated parenteral administration. US MM-6 (NCT03173092) enrolled transplant-ineligible patients with newly diagnosed MM to receive all-oral ixazomib-lenalidomide-dexamethasone (IRd; ≤39 cycles or until progression or toxicity) following three cycles of bortezomib-based induction.